Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study

Abstract Osimertinib is the standard first-line options for patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). Co-mutations in TP53 results in poor survival for patients. However, the studies on treatment options and clinical outcomes of patients with EGFR-TP53 co- mutation are...

Full description

Saved in:
Bibliographic Details
Main Authors: Jixian Li, Xiang Zhan, Mengqing Shao, Renya Zeng, Jianan Li, Hui Zhu, Alei Feng, Zhe Yang, Wang Jing
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
NSCLC
Osimertinib
EGFR
TP53
Chemotherapy
Online Access:https://doi.org/10.1038/s41598-025-03422-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-03422-9

Similar Items